Free Trial

Bio-Rad Laboratories (BIO) Stock Price, News & Analysis

Bio-Rad Laboratories logo
$241.65 -2.33 (-0.95%)
As of 03:58 PM Eastern

About Bio-Rad Laboratories Stock (NYSE:BIO)

Key Stats

Today's Range
$238.54
$246.76
50-Day Range
$216.69
$254.32
52-Week Range
$211.43
$387.99
Volume
297,063 shs
Average Volume
343,358 shs
Market Capitalization
$6.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$324.25
Consensus Rating
Moderate Buy

Company Overview

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Bio-Rad Laboratories Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
98th Percentile Overall Score

BIO MarketRank™: 

Bio-Rad Laboratories scored higher than 98% of companies evaluated by MarketBeat, and ranked 37th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bio-Rad Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Bio-Rad Laboratories has only been the subject of 4 research reports in the past 90 days.

  • Read more about Bio-Rad Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for Bio-Rad Laboratories are expected to grow by 15.17% in the coming year, from $10.81 to $12.45 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bio-Rad Laboratories is -3.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bio-Rad Laboratories is -3.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Bio-Rad Laboratories has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Bio-Rad Laboratories' valuation and earnings.
  • Percentage of Shares Shorted

    4.83% of the float of Bio-Rad Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    Bio-Rad Laboratories has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bio-Rad Laboratories has recently decreased by 26.98%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Bio-Rad Laboratories does not currently pay a dividend.

  • Dividend Growth

    Bio-Rad Laboratories does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.83% of the float of Bio-Rad Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    Bio-Rad Laboratories has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bio-Rad Laboratories has recently decreased by 26.98%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Bio-Rad Laboratories has a news sentiment score of 1.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Bio-Rad Laboratories this week, compared to 7 articles on an average week.
  • Search Interest

    8 people have searched for BIO on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Bio-Rad Laboratories to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bio-Rad Laboratories insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    17.83% of the stock of Bio-Rad Laboratories is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    65.24% of the stock of Bio-Rad Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bio-Rad Laboratories' insider trading history.
Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

BIO Stock News Headlines

Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
See More Headlines

BIO Stock Analysis - Frequently Asked Questions

Bio-Rad Laboratories' stock was trading at $328.51 at the beginning of the year. Since then, BIO shares have decreased by 26.4% and is now trading at $241.65.
View the best growth stocks for 2025 here
.

Bio-Rad Laboratories, Inc. (NYSE:BIO) posted its quarterly earnings data on Thursday, May, 1st. The medical research company reported $2.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.73 by $0.81. Bio-Rad Laboratories's revenue for the quarter was down 4.2% compared to the same quarter last year.
Read the conference call transcript
.

The following companies are subsidiaries of Bio-Rad Laboratories: Dropworks Inc., Celsee, Raindance Technologies Limited, GnuBIO Inc., Bio-Rad AbD Serotec GmbH, Propel Labs - Cell Sorting System Division, QuantaLife, and more.

Shares of BIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Rad Laboratories investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
5/01/2025
Today
6/30/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NYSE:BIO
Employees
7,700
Year Founded
1952

Price Target and Rating

Average Stock Price Target
$324.25
High Stock Price Target
$392.00
Low Stock Price Target
$245.00
Potential Upside/Downside
+34.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
22.35
P/E Growth
N/A
Net Income
-$1.84 billion
Pretax Margin
-108.23%

Debt

Sales & Book Value

Annual Sales
$2.57 billion
Cash Flow
$10.29 per share
Price / Cash Flow
23.48
Book Value
$234.52 per share
Price / Book
1.03

Miscellaneous

Free Float
22,361,000
Market Cap
$6.58 billion
Optionable
Optionable
Beta
0.93

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NYSE:BIO) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners